Scarica l'app Stockscreener
131.65
0.62%
0.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Benjamin Edwards Inc. Has $16.60 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
FDA Priority Review For New HIV Combo Might Change The Case For Investing In Gilead Sciences (GILD) - simplywall.st
Strs Ohio Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Robertson Stephens Wealth Management LLC Has $6.27 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term Story - Yahoo Finance
The Freelux Project Announces “The Butch Queen’s Brunch & Conversations Tour” Powered by Gilead Sciences - GLAAD
Gilead Sciences, Inc. $GILD Shares Sold by New York State Teachers Retirement System - MarketBeat
Oppenheimer & Co. Inc. Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Jennison Associates LLC Buys 741,044 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
US Bancorp DE Has $105.44 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences - The AI Journal
Danske Bank A S Sells 45,529 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Fifth Third Bancorp Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
GC Wealth Management RIA LLC Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Cash Flow – TSX:GILD - TradingView
Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Revenue Breakdown – TSX:GILD - TradingView
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions Highlighted - MarketBeat
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now? - Insider Monkey
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir - European AIDS Treatment Group
Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish? - Barchart.com
Gilead Sciences, Inc. $GILD Shares Sold by Verity Asset Management Inc. - MarketBeat
Gilead Sciences, Inc. $GILD Position Trimmed by State of New Jersey Common Pension Fund D - MarketBeat
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst - MarketBeat
Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone - Stock Titan
Is It Time To Revisit Gilead Sciences (GILD) After Recent Share Price Pullback - Yahoo Finance
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead Sciences (NASDAQ:GILD) CEO Sells $1,291,600.00 in Stock - MarketBeat
Vanguard reports 93.3M-share, 7.51% stake in Gilead Sciences (NASDAQ: GILD) - Stock Titan
Gilead Sciences CEO Daniel O’Day sells over $1.29m in stock - Investing.com Nigeria
Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade - Stock Titan
Assessing Whether Gilead Sciences (GILD) Looks Undervalued After Recent Share Price Performance - simplywall.st
Gilead Sciences Stock: Three Acquisitions, Four Launches, and a 20% Discount to Wall Street’s Target - TIKR.com
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir - BioSpace
GILD: Gilead's New HIV Treatment Gains FDA Acceptance - GuruFocus
Kymera Therapeutics earnings on deck after Gilead deal milestone By Investing.com - Investing.com Nigeria
Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences stock edges higher as FDA grants priority review for HIV treatment - Traders Union
FDA accepts Gilead’s HIV treatment combination for review - Investing.com
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know - MEXC
Daniel O'Day (GILD) files Form 144 to sell 10,000 performance shares - Stock Titan
Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Gilead Sciences (GILD) Stock Lands $7.8B Arcellx Deal — Is This the Buy Opportunity? - CoinCentral
Gilead Sciences, Inc. completed the acquisition of 77.2% stake in Arcellx, Inc. from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others. - marketscreener.com
Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here. - Barron's
Gilead Sciences (GILD) Completes Acquisition of Arcellx, Inc. - GuruFocus
Gilead Sciences completes acquisition of Arcellx ahead of potential commercial launch of Anito-cel - marketscreener.com
Gilead Completes $7.8 Billion Acquisition of Arcellx - Contract Pharma
Gilead Sciences Finalizes $7.8 Billion Acquisition of Arcellx - marketscreener.com
Recent Arcellx deal leaves Gilead Sciences stock consolidating amid persistent oversold signals - Traders Union
Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx, Securing Full Control of CAR T Therapy Anito-cel - citybiz
Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx to Accelerate Launch of Anito-cel CAR T Therapy for Multiple Myeloma 1 - Minichart
Gilead Sciences Completes Acquisition of Arcellx and Anito-cel - TipRanks
Gilead fully acquires Arcellx (NASDAQ: ACLX) as tender offer and merger close - Stock Titan
Gilead completes $7.8 billion acquisition of Arcellx - Investing.com
Gilead Sciences reports new GTPase KRAS G12D inhibitors and degraders - BioWorld News
Gilead completes $7.8 billion acquisition of Arcellx By Investing.com - Investing.com Canada
Gilead (NASDAQ: GILD) closes Arcellx deal, gains full control of anito-cel - Stock Titan
Gilead Sciences (ACLX) to close merger; 77.2% tendered, $115 cash plus CVR - Stock Titan
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel - Business Wire
Mitsubishi UFJ Trust & Banking Corp Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
M&T Bank Corp Sells 147,548 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
1.39%
3.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):